News Releases

2007

Dec.20,2007 Ono Enters into License Agreement with Nissan Chemical for New Therapeutic Agent for Thrombocytopenia (59.3KB)
Dec.12,2007 Announcement of JNDA Submission in Japan for SITAGLIPTIN,a New Oral Treatment of Type II Diabetes (29.2KB)
Nov.15,2007 Ono Enters into Service Agreement with Nissin for Use of New Carcinogenicity Evaluation System, Developed by Nissin, for Pharmaceutical Compounds (59.8KB)
Nov.08,2007 Revisions of Full Year Business Forecasts for FY 2007 (79.4KB)
Nov.05,2007 Ono Enteres Into New Drug Discovery Agreement on Kinases with Locus Pharmaceuticals, Inc. (76.9KB)
Oct.30,2007 Initiation of Development of “ONO-4538/MDX-1106ÂEFully Human Anti-PD-1 Antibody for Hepatitis C in US (19.3KB)
Oct.11,2007 Announcement on Completion of Acquisition of the Company's Own Shares (59.3KB)
Sep.28,2007 Exelon® patch receives European Union approval, the first skin patch therapy to treat Alzheimer's disease (100KB)
Aug.06,2007 Ono Enters into License Agreement with CeNeS Limited - New Intravenous Anaesthetic - (23.7KB)
Aug.06,2007 Announcement on Acquisition of the Company's Own Shares (60.6KB)
Jul.23,2007 Novartis Receives Recommendation for Approval of Patch Formulation of Exelon, Only Skin Patch for the Treatment of Alzheimer's Disease in EU (211KB)
Jul.10,2007 Novartis Receives First Worldwide Approval in US for Exelon Patch, the First and Only Skin Patch for the Treatment of Alzheimer's Disease (159KB)
Jul.05,2007 New Data Released at ADA Showed that Initial Combination Therapy with sitagliptin and Metformin Led to Significant Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes (Second Report) (75.5KB)
Jul.02,2007 Data Released at ADA showed efficacy in the Investigational use of a new oral medicine for type 2 diabetes, sitagliptin, and other medicine as Initial Combination Therapy (First Report) (73.9KB)
Jun.28,2007 Resolutions at the 59th Annual Shareholders Meeting (58.6KB)
Jun.20,2007 The Company Views and Policy on the Decrease in Number of Shares in One Trading Unit (48.4KB)
Jun.11,2007 Launch of Staybla® Tablets 0.1mg, a Drug for Overactive Bladder (59.9KB)
May.14,2007 Revision on Compensation for Members of the Board of Directors (48.7KB)
May.14,2007 The Company's Thoughts on the Shareholder Proposal (64.1KB)
Apr.18,2007 Announcement of Approval of Staybla®Tablets 0.1mg, a Drug for Overactive Bladder (51.7KB)
Apr.10,2007 Regarding Today's Media Report (51.0KB)
Apr.05,2007 Merck & Co, Inc. (Whitehouse Station, New Jersey, USA) Announced Approval of SITAGLIPTIN, a New Oral Treatment of Diabetes, in the European Union (115KB)
Mar.26,2007 Announcement on Cancellation of the Company's Own Shares (57.7KB)
Mar.26,2007 Announcement on Completion of Acquisition of the Company's Own Shares (59.4KB)
Feb.27,2007 Announcement of Establishment of Strategic Alliance Headquarters (61.1KB)
Feb.27,2007 Ono resolved increase in dividends projected for the fiscal year 2006(ending on March 31st,2007) (148KB)